ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1659

Identification of Long Noncoding RNA RP11-2B6.2 As a Positive Regulator through Type I Interferon Pathway in Lupus Nephritis

Yuanjia Tang1, Zhuojun Liao1, Zhixin Xue1, Lingling Wu1 and Nan Shen1,2,3,4, 1Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 4Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: SLE and interferons

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Long noncoding RNAs (lncRNAs) have recently been identified to be tightly linked to diverse human diseases. Systemic lupus erythematosus (SLE) is a common autoimmune disease. Renal involvement is the most frequent and serious complication. Type I interferon (I IFN) and a group of inflammatory cytokines induced by type I IFN in human renal mesangial cells(HRMCs) play a vital role in lupus nephritis(LN). In this study we screened and investigated the contribution of the lncRNA RP11-2B6.2 to the pathogenesis of LN involved in the abnormal activation of type I IFN pathway.

Methods:

The high throughput RNA-seq data from kidney biopsies of LN patients and controls was applied to screen for candidate lncRNA and confirm its relationship with clinical data. Rapid amplification of cDNA ends (RACE) was adopted to identify the full length and exact sequences of lncRNA. In situ hybridization was adopted to identify the lncRNA location of cell nucleus and cytoplasm. Quantitative real-time polymerase chain reaction(RT-qPCR) and western blotting was used to detect the RNA and protein expression of lncRNA and individual genes relevant to type I IFN pathway respectively. Dual-luciferace reporter assay was used to detect the promoter transcriptional activity of genes.

Results:

The expression of lncRNA RP11-2B6.2 was significantly increased in the kidney tissues from LN patients compared with those from healthy controls, and positively correlated with the degree of disease activity and renal injury. Additionally, the expression of LncRNA RP11-2B6.2 can be stimulated by type I IFN. Silencing RP11-2B6.2 significantly reduced the expression of a group of interferon-stimulating genes(ISGs) including IFIT1, OAS1, etc., Furthermore, lncRNA RP11-2B6.2 affected the expression of IFN alpha and beta receptor subunit 1 (IFNAR1) and its promoter transcriptional activity, phosphorylation of Jak1 and Stat1, and the luciferase activity induced by interferon stimulated response element(ISRE).

Conclusion:

Long noncoding RNA RP11-2B6.2 is a positive regulator of the type I IFN signaling pathway in LN. LncRNA RP11-2B6.2 may contribute to the pathogenesis of LN and provide a potentially therapeutic target.


Disclosure: Y. Tang, None; Z. Liao, None; Z. Xue, None; L. Wu, None; N. Shen, None.

To cite this abstract in AMA style:

Tang Y, Liao Z, Xue Z, Wu L, Shen N. Identification of Long Noncoding RNA RP11-2B6.2 As a Positive Regulator through Type I Interferon Pathway in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/identification-of-long-noncoding-rna-rp11-2b6-2-as-a-positive-regulator-through-type-i-interferon-pathway-in-lupus-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-long-noncoding-rna-rp11-2b6-2-as-a-positive-regulator-through-type-i-interferon-pathway-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology